Restoring airway epithelial barrier dysfunction: a new therapeutic challenge in allergic airway disease*

Brecht Steelant1, Sven F. Seys1, Guy Boeckxstaens2, Cezmi A. Akdis3, Jan L. Ceuppens1, Peter W. Hellings1,4,5,6

1 Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium
2 Translational Research in Gastro Intestinal Disorders, KU Leuven, Leuven, Belgium
3 Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland
4 Clinical Division of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Belgium
5 Department of Otorhinolaryngology, University Hospitals Ghent, Belgium
6 Department of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

Abstract

An intact functional mucosal barrier is considered to be crucial for the maintenance of airway homeostasis as it protects the host immune system from exposure to allergens and noxious environmental triggers. Recent data provided evidence for the contribution of barrier dysfunction to the development of inflammatory diseases in the airways, skin and gut. A defective barrier has been documented in chronic rhinosinusitis, allergic rhinitis, asthma, atopic dermatitis and inflammatory bowel diseases. However, it remains to be elucidated to what extent primary (genetic) versus secondary (inflammatory) mechanisms drive barrier dysfunction. The precise pathogenesis of barrier dysfunction in patients with chronic mucosal inflammation and its' implications on tissue inflammation and systemic absorption of exogenous particles are only partly understood. Since epithelial barrier defects are linked with chronicity and severity of airway inflammation, restoring the barrier integrity may become a useful approach in the treatment of allergic diseases.

We here provide a state-of-the-art review on epithelial barrier dysfunction in upper and lower airways as well as in the intestine and the skin and on how barrier dysfunction can be restored from a therapeutic perspective.

Key words: tight junctions, allergic rhinitis, chronic rhinosinusitis, trans-epithelial electric resistance, fluticasone, EGF signaling

Key points
- Restoring nasal epithelial barrier function
- Epithelial barrier dysfunction is linked to allergic diseases
- Corticosteroids upregulate tight junction

Introduction

The airway epithelium is the first site of contact with inhaled particles like allergens or microorganisms. It is a pseudo-stratified columnar epithelial barrier that prevents the penetration of possible harmful particles [1]. Besides protecting the host by a physical barrier, airway epithelial cells are an integral part of the innate immune response [2, 3]. Mucociliary clearance, release of antimicrobial peptides and the production of chemokines and cytokines all contribute to eradicating possible harmful organisms from entering the body by inducing an appropriate immunological response [4]. Epithelial cells express different receptors such as toll like receptors (TLR) [5], protease activated receptors, NOD-like receptors and c-type lectin receptors [6]. These pattern recognition receptors sense the environment for the presence of danger associated- and pathogen associated molecular patterns and, thereby contribute to the induction of an immune response. The immunological role of airway epithe-

List of Abbreviations. EGF: epidermal growth factor; ERK: extracellular signal-regulated kinases; JAM-A: junctional adhesion molecule A; MAPK: Mitogen-activated protein kinase; TEER: trans-epithelial electrical resistance; TJ: tight junction; TLR: toll like receptor; TNF: tumor necrosis factor; TSLP: Thymic stromal lymphopoietin; ZO: zonula occludens
Epithelial cells have nicely been discussed elsewhere (2-4, 6). The physical barrier to the external environment is created by means of different junctional complexes that connect epithelial cells to one another (7, 8). Tight junctions (TJs) are the most apically located epithelial junctions and are key regulators in the homeostasis of ions, water and certain macromolecules (8). TJs form a rate-limiting barrier to inhaled pathogens. Below the TJs are the adherens junctions. Adherens junctions are essential for gene regulation, linked with cell proliferation and differentiation (9) and are important in maintaining cell-cell contact (10). Desmosomes are in close connectivity with adherens junctions and are associated with cell adhesion (11, 12), proliferation and differentiation (13).

TJs consist of different transmembrane and intracellular proteins (7, 14, 15). Transmembrane proteins such as the claudin family (16), junctional adhesion molecule A, occludin and tricellulin form heterodimer/homodimers to seal off the paracellular space between airway epithelial cells. In addition, different intracellular scaffold proteins like the zonula occludens (ZO) family, multi-PDZ domain protein 1, membrane-associated guanylate kinase and cingulin connect the transmembrane proteins to the cytoskeleton (8, 12). Claudins are four-transmembrane spanning proteins, specialized in the regulation of permeability and TJ resistance (16). Nowadays, more than 24 claudin members have been identified (16, 17). Based on their effect on airway epithelial barrier function, claudins can be divided in two groups: the pore forming claudins, and the barrier forming claudins. The pore forming claudins, such as claudin-2 (18) and claudin-7 (19) increase the permeability to anions/cations, while the barrier forming claudins such as claudin-1 (18) and claudin-4 (21) tighten the epithelial barrier function, with the reduction in cation/anion permeability (22). On top, TJs are linked with two different pathways: the pore pathway and the leak pathway (8). The leak pathway is a low capacity, paracellular route that does not discriminate between solutes on the basis of charge and allows limited flux of large molecules. ZO-1 and occludin have been implicated in leak pathway regulation (8). The pore pathway is a high-capacity, size and charge-selective paracellular route, regulated by the claudin family (8). Taken together, TJs are not only passive structures sealing off the paracellular space between neighboring epithelial cells, but are actively involved in different pathways with distinct functions.

Adherens junctions are composed of extracellular E-cadherin and the cytoplasmic p120-catenin and β-catenin (7, 23). Together with TJ, adherens junctions form an apical junctional complex, essential in controlling epithelial cell-to-cell contact as well as regulation of the actin cytoskeleton, intracellular signaling pathways and transcriptional regulation.

Beneath the apical junctional complex are the desmosomes. Desmosomes are built of desmoglein and desmocollin, which are connected to the cytoskeleton via desmoplakin, plakoglobin and plakophillin (11, 13).

A disturbed composition of interepithelial junctions will increase the accessibility of foreign particles to the submucosal region. Impaired airway epithelial barrier function may be an important, yet underrated, key player in the pathogenesis of allergic airway diseases. As a consequence, restoring barrier function might be a useful strategy in allergic airway disease treatment. This review, therefore, focuses on mechanisms that can restore epithelial barrier function.

### Barrier dysfunction in chronic inflammatory conditions: state-of-the-art

For decades, chronic inflammatory diseases such as allergic rhinitis and allergic asthma were assumed to be caused by an unbalanced, over-reactive immunological response, mostly driven...
by activated Th2 cells. However, this assumption cannot explain the full spectrum of the different inflammatory pathologies. Recently, there is growing interest in the epithelial barrier function as a major contributor to the pathophysiology of chronic inflammatory diseases. Opening of TJs facilitates the entrance of allergens and other harmful particles in the mucosal and submucosal region with the activation of the immune and inflammatory system as a consequence. On the other hand, opening of TJs also facilitates drainage of inflammation, which underscores the importance of a tight regulation of the epithelial barrier. We here give an overview of barrier dysfunction associated with allergic diseases in the skin (24), the intestine (25) and the airways (26) (Table 1).

Atopic dermatitis is a common chronic inflammatory condition of the skin (27), with a high prevalence in the Westernized countries (28, 29). The skin maintains its integrity by two distinct barrier functions: the stratum corneum and the TJs (27). Defects in the stratum corneum either by reduced lipid levels (31, 32) or by acquired/genetic mutation in the flaggrin gene (33) or in other epidermal differentiation proteins, lead to the skin lesions typical for atopic dermatitis. TJ defects in the epidermis have recently been described by De Benedetto and colleagues (34).

Ex vivo studies on epidermal biopsies demonstrated a reduced expression of claudin-1 and claudin-23 with bioelectric defects (24). Interestingly, claudin-1 expression correlated inversely with the number of eosinophils in the skin, showing that claudin-1 affects the the immune response to environmental allergens. Increased epithelial permeability is also found in the intestine of patients with inflammatory bowel diseases like Crohn’s disease or ulcerative colitis (34, 35). Early evidence obtained from freeze-fracture electron microscopy analysis revealed a decreased expression of tight junction strands in Crohn’s disease together with the breakdown of TJ strands (35). A clear reduction was found for TJ proteins occludin and the sealing claudins; claudin-5 and claudin-8. In contrast, an upregulation of claudin-2 protein was reported in patients with Crohn’s disease (36), resulting in a changed TJ architecture. In ulcerative colitis, the epithelial barrier is impaired by erosion/ulcer-type lesions and epithelial apoptosis causing local leaks and generalized TJ alterations increasing the basal permeability (34, 37). Functional dyspepsia is a gastro-intestinal disorder, affecting up to 20% of the population (38). Despite the high prevalence, no clear treatment is available and the mechanisms contributing to this pathology are only partially revealed. Low grade inflammation in these subjects was found to be linked to increased intestinal permeability. Expression of occludin, E-cadherin and β-catenin were found to be decreased in intestinal biopsies (39).

Evidence for barrier dysfunctions underlying the pathology in upper and lower airways has only recently been obtained. The first evidence for barrier dysfunction in the lower airways was found in 2008. Patients with mild asthma had a disturbed expression of ZO-1 and β-catenin as shown by semi-quantitative immunofluorescence staining of bronchial biopsies (40). The functional significance of the loss of ZO-1 and β-catenin was further illustrated in primary airway epithelial cell cultures and on bronchial biopsies. Primary bronchial epithelial cells, derived from asthmatics and cultured in vitro at air-liquid interface, showed a reduced epithelial integrity, together with a reduced expression of ZO-1 and occludin. This was also confirmed on bronchial biopsies of patients with asthma (41). More detailed information on the regulation of epithelial barrier function in the lower airways has been extensively described elsewhere (7, 15, 42, 43). In the upper airways, Soyka et al. (44) have demonstrated a leaky epithelium in patients with chronic rhinosinusitis with/without nasal polyps. This leaky epithelium was linked with a decreased expression of occludin and claudin-4 in nasal biopsies (44).
Steelant et al. group recently confirmed a disrupted TJ arrangement in the nasal cavity of patients with allergic rhinitis (Figure 2). We have shown by experiments in vitro, ex vivo and in vivo (in a mouse model of house dust mite induced allergic airway inflammation) that the barrier function is impaired and that this is due to a decreased expression of occludin and ZO-1 (26). Interestingly, we showed that different TJ proteins (i.e. occludin and ZO-1) were involved in the pathology of allergic rhinitis compared to the TJ proteins (occludin and claudin-4) linked with the pathology of chronic rhinosinusitis, illustrating that the regulation of TJ function can be linked with the disease origin. Indeed, Kast et al. showed that each epithelial cell, depending on the site of isolation, had its own, unique expression pattern reflecting its specific function within the organism (45). In the upper airways, Th2 inflammation is presumably the causative driving factor for epithelial dysfunction. Stimulation of epithelial cells from both allergic rhinitis and chronic rhinosinusitis patients with IL-4 resulted in a decreased epithelial integrity.

Although epithelial barrier defects are linked with different diseases; it remains unclear whether barrier dysfunction is a primary defect, participating to the onset of inflammation or only a consequence of sustained inflammation. Sunaert and colleagues showed that t-cell induced colonic inflammation can change colonic epithelial integrity even before the development of colitis (46). This suggests that defective epithelium is not only a consequence of inflammation but also an early defect that might actually strengthen inflammation by increasing the amount of foreign antigens in the mucosa. Noteworthy, epithelial cells from patients cultured in vitro for several weeks still show a decreased epithelial integrity, even in the absence of any inflammation. This point out towards an intrinsic effect in TJ function or a certain memory function in epithelial cells exposed to inflammation. Indeed, epigenetics might play a role in the memory effect. It has been shown that IL-13 induces long-lasting DNA methylation changes in airway epithelial cells from asthmatics (47), contributing to the phenotype of asthma. In conclusion, defective epithelial barrier is linked with pathology but if this is a primary intrinsic effect, or a result of inflammation needs to be further elucidated.

### Models to study nasal barrier (dys)function

#### Epithelial cell culture system in vitro

Primary nasal epithelial cells are the most relevant cells to be studied in vitro. A number of non-invasive techniques (nasal

<table>
<thead>
<tr>
<th>Technique</th>
<th>Method of isolation</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Epithelial cell culture in vitro</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary epithelial cells</td>
<td>Non-surgical; scraping</td>
<td>• Well tolerated&lt;br&gt;• Repeated isolation possible&lt;br&gt;• No anesthesia</td>
<td>• Limited cell numbers&lt;br&gt;• Culture difficulties</td>
</tr>
<tr>
<td>Surgical</td>
<td>--</td>
<td>• Number of cells isolated (800.000 cells/isolation)&lt;br&gt;• Comparison pathology and health</td>
<td>• Regular access to tissue&lt;br&gt;• Inter variability&lt;br&gt;• Intra variability&lt;br&gt;• Culture difficulties</td>
</tr>
<tr>
<td>Epithelial cell lines</td>
<td>--</td>
<td>• Unlimited number of cells&lt;br&gt;• Easy maintenance</td>
<td>• Morphological differences&lt;br&gt;• Different cellular responses&lt;br&gt;• Biochemical characteristics are different</td>
</tr>
<tr>
<td><strong>Mucosal explant model</strong></td>
<td>Biopsies (local anaesthesia)</td>
<td>• documents patients mucosal status at time of isolation</td>
<td>• Limited viability&lt;br&gt;• Limited number of biopsies harvested</td>
</tr>
<tr>
<td><strong>Murine models</strong></td>
<td>--</td>
<td>• Time- and dose-response experiments&lt;br&gt;• Study of underlying inflammatory mechanisms</td>
<td>• Relevance needs to be confirmed in humans</td>
</tr>
</tbody>
</table>
Therapeutic challenge for epithelial barrier dysfunction

brushing, nasal scrapings, nasal smears, blown secretions) can be used to sample human nasal tissue or cells [46]. These non-surgical procedures are well tolerated, do not require anesthesia and can easily be repeated. The main disadvantage of these techniques is the limited number of cells that can be recovered, and which is insufficient to grow a monolayer of epithelial cells. A higher number of nasal epithelial cells can be harvested from patients undergoing surgery. The harvested tissue (i.e. inferior turbinate) is enzymatically dissociated and so a purified epithelial cell population is obtained [47, 48]. Although primary nasal epithelial cells are the best cells to study barrier function as they mimic the patient’s condition, some limitations have to be considered. The number of epithelial cells isolated from one patient is still limited (average 800,000 cells/isolation), there is an inter- and intra-variability within cultures, a possible risk for bacterial contamination and technical difficulties in culturing [48].

Epithelial cell lines, derived from carcinomas, can be used to overcome the limitations of isolating primary epithelial cells from tissue. Different cell lines, from both the upper and lower airways, are available. The RPMI 2650 is a nasal epithelial cell line, derived from a human nasal anaplastic cell carcinoma, unfortunately with very poor differentiation [50]. In culture, RPMI 2650 cells do not express functional TJs and will not form a monolayer [11]. Therefore, they are not suitable to study epithelial barrier regulation. A better alternative is the human lung adenocarcinoma cell line, Calu-3. Calu-3 cells express TJs and form a polarized monolayer in vitro [52]. Another bronchial epithelial cell line is 16HBE [53], with similar culture characteristics as Calu-3 cells. Despite the easy maintenance and the unlimited amount of cells, epithelial cell lines do not have the same cellular responses, morphology and biochemical characteristics as primary cells.

To evaluate epithelial barrier function, epithelial cells (either primary or epithelial cell lines) are seeded on transwell inserts. At a high seeding density, epithelial cells will grow to a confluent monolayer expressing TJs. After reaching a confluent monolayer, the liquid is removed from the apical side, so that epithelial cells can further differentiate at the air-liquid interface. By measuring the trans-epithelial electrical resistance (TEER), the epithelial integrity can be evaluated and followed over time. Besides TEER,

Figure 3. Restoration of epithelial barrier function. A). Activation of TLR2 or TLR9 stimulates PKC function and the expression of different TJ components. TLR3 activation results in expression of miRNAs with downregulation of TJ function. miRNAs function is suppressed by specific inhibitors, which results in upregulation of TJs and barrier function. Lipoxin A4 and apolipoprotein A1 can directly or indirectly (via mechanisms not fully understood) stimulate the expression of TJs. B). Binding of TSLP on its receptor stimulates the expression of TJ components. Activation of EGF-R results either in direct stimulation of TJ function or via its downstream components. Inhibition of SRC inhibits the activation of MLCK genes and therefore no phosphorylation of MLC and no internalization of TJs follows. C). Corticosteroids have different mechanisms of action. On the one hand, corticosteroids can bind to the steroid receptor and translocate to the nucleus where they suppress the activation of MLCK. Phosphorylation of MLC by MLCK is inhibited and the contraction of the actomyosin ring is prevented with no internalization of TJ complexes. On the other hand, corticosteroids can upregulate MKP-1 function. MKP-1 dephosphorylates p38, ERK, c-Jun N-terminal kinases resulting in an upregulation of barrier function.
Steelant et al.

Since house dust mite extract can cleave TJs (57), the mucosal permeability can be evaluated using fluorescein labeled dextran. After intranasal instillation of the dextran tracer, the passage of the tracer to the serum can be evaluated and is a surrogate marker for mucosal permeability.

Mechanisms involved in restoration of barrier dysfunction
As a defect in the epithelial barrier function is a hallmark of mucosal inflammation in different allergic diseases, restoration of barrier defects might reduce the excessive penetration of inhaled allergens and foreign particles into the submucosal regions, ultimately resolving the activation of the immune system and the occurrence of symptoms. A wide variety of possible mechanisms to restore barrier function are reported in literature (Table 3) (Figure 3).

Innate immune function
TLR are essential receptors in inducing an innate immune response against invading pathogens. TLR2 is recruited to the

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Tight junction proteins</th>
<th>Cells</th>
<th>Barrier function</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pam3CysSK4; Peptidoglycan</td>
<td>OCCL ↓; ZO-1 ↑; CLDN-1 ↑</td>
<td>Calu-3</td>
<td>TEER ↑; Fluorescein sodium ↓</td>
<td>(59)</td>
</tr>
<tr>
<td>Poly(L-C</td>
<td>JAM-A ↓</td>
<td>HNEC</td>
<td>TEER =</td>
<td>(61)</td>
</tr>
<tr>
<td>miRNA-146a</td>
<td>OCCL ↑; CLDN-1 ↑; JAM-A ↑</td>
<td>HNEC</td>
<td>TEER ↑</td>
<td>(62)</td>
</tr>
<tr>
<td>CpG-DNA</td>
<td>OCCL ↑; ZO-1,2,3 ↑; CLDN-1,4,7 ↑</td>
<td>HBEC</td>
<td>TEER ↑; FD4 ↓</td>
<td>(69)</td>
</tr>
<tr>
<td>Apolipoprotein A1</td>
<td>OCCL ↑; ZO-1 ↑; CLDN-1 ↑</td>
<td>HBOC</td>
<td>TEER ↑</td>
<td>(74)</td>
</tr>
<tr>
<td>Lipoxin A4</td>
<td>OCCL ↓; ZO-1 ↑; CLDN-1 ↑</td>
<td>16HBE</td>
<td>TEER ↑</td>
<td>(76)</td>
</tr>
</tbody>
</table>

Cytokines and growth factors

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Tight junction proteins</th>
<th>Cells</th>
<th>Barrier function</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGF</td>
<td>---</td>
<td>Caco-2; T-84 cells</td>
<td>TEER ↑; Mannitol ↓</td>
<td>(80)</td>
</tr>
<tr>
<td>EGF</td>
<td>OCCL ↑; ZO-1 ↑</td>
<td>Caco-2</td>
<td>TEER ↑; Insulin ↓</td>
<td>(81)</td>
</tr>
<tr>
<td>EGF</td>
<td>OCCL ↑; ZO-1 ↑</td>
<td>HBEC</td>
<td>TEER ↑</td>
<td>(41)</td>
</tr>
<tr>
<td>TSLP</td>
<td>OCCL ↑; CLDN-1,4,7 ↑</td>
<td>HBEC</td>
<td>TEER ↑; Mannitol ↓</td>
<td>(86)</td>
</tr>
<tr>
<td>Src-kinase inhibitor</td>
<td>OCCL ↑; E-cadherin ↑; p120 catenin ↑</td>
<td>HBEC</td>
<td>TEER ↑; FD4 ↓</td>
<td>(89)</td>
</tr>
</tbody>
</table>

Corticosteroids

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Tight junction proteins</th>
<th>Cells</th>
<th>Barrier function</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone</td>
<td>--</td>
<td>Patients</td>
<td>Lactulose/mannitol ↓</td>
<td>(95)</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>CLDN-4 ↑; CLDN-2 ↓</td>
<td>Caco-2</td>
<td>TEER ↑; LY =</td>
<td>(96)</td>
</tr>
<tr>
<td>Prednisone; Dexamethasone</td>
<td>--</td>
<td>Caco-2</td>
<td>TEER ↑; Insulin ↓</td>
<td>(97)</td>
</tr>
<tr>
<td>Dexamethasone; Fluticasone propionate</td>
<td>OCCL ↑; ZO-1 ↑</td>
<td>Calu-3, 16HBE</td>
<td>TEER ↑; FD4 ↓; FD10 ↓</td>
<td>(98)</td>
</tr>
<tr>
<td>Fluticasone propionate</td>
<td>OCCL ↑; ZO-1 ↑</td>
<td>HNEC</td>
<td>TEER ↑; FD4 ↓</td>
<td>(26)</td>
</tr>
</tbody>
</table>


Fluorescein-labeled dextran molecules can be used to study epithelial permeability as this tracer will migrate through the paracellular space from the apical side to the basolateral side.

Explant model
Although in vitro evaluation of epithelial barrier integrity and permeability is a widely used and accepted technique to study barrier function, it is a static and time consuming system. Nasal mucosal explants may be more suitable to evaluate mucosal integrity. Mucosal biopsies can easily be taken under local anesthetics and used as explants. With the use of Ussing chambers (54), the mucosal integrity can be evaluated within hours post-isolation. A disadvantage of an explant model, however, is that stimulation studies that last for multiple hours cannot be performed on explants, as the viability of the explants is only preserved for a maximum of 6 hours.

Murine models of allergic airway inflammation
Murine models can be used to study the effect of allergens or other possible harmful substances on barrier function (55, 56). We have developed a mouse model to study changes in mucosal permeability induced by house dust mite extract (26). Since house dust mite extract can cleave TJs (57), the mucosal permeability can be evaluated using fluorescein labeled dextran. After intranasal instillation of the dextran tracer, the passage of the tracer to the serum can be evaluated and is a surrogate marker for mucosal permeability.

Mechanisms involved in restoration of barrier dysfunction
As a defect in the epithelial barrier function is a hallmark of mucosal inflammation in different allergic diseases, restoration of barrier defects might reduce the excessive penetration of inhaled allergens and foreign particles into the submucosal regions, ultimately resolving the activation of the immune system and the occurrence of symptoms. A wide variety of possible mechanisms to restore barrier function are reported in literature (Table 3) (Figure 3).

Innate immune function
TLR are essential receptors in inducing an innate immune response against invading pathogens. TLR2 is recruited to the
apical site of airway epithelial cells in the presence of pathogenic bacteria (58). In Calu-3 bronchial epithelial cells, Pam3CysSK4 and peptidoglycan ligand-induced TLR2 activation significantly increased TEER in a dose-dependent manner, accompanied with a reduction in fluorescein sodium permeability (59). This enhancement in barrier function was associated with an upregulation in expression levels of TJ proteins ZO-1 and claudin-1 and a downregulation of occludin. 

TLR3 recognizes viral double-stranded RNA and its synthetic analogue polyinosinic-polyricidylic acid (polyI:C) (60). PolyI:C induced activation of TLR3 in HNEC resulted in a decreased expression of JAM-A without changing epithelial integrity (61). Interestingly, polyI:C activation resulted in the upregulation of micro RNA-146a via the TLR3-mediated signaling pathways phosphoinositide 3-kinase c-Jun N-terminal kinases and NF-κB (62). Micro-RNAs are a class of endogenous noncoding RNAs, regulating various biological processes (63) including inflammatory responses in allergic inflammation in the nasal mucosa (64) but also the formation of TJs and epithelial barriers (65, 66, 67). When HNEC were treated with inhibitors of microRNAs, i.e. miR-146a mimic, this resulted in an increased expression of claudin-1, occludin and JAM-A together with an increased barrier function (62). Furthermore, miR-146a mimic prevented the secretion of IL-8 and TNFα. Thus, interfering with microRNAs may represent a potential therapy for human upper airway viral diseases as Influenza A virus (67) and respiratory syncytial virus (68) induce the expression of microRNAs and downregulate barrier function. The activation of TLR9 by CpG-DNA or other TLR9 ligands enhanced barrier function of bronchial epithelial cells in vitro. Treatment with CpG-DNA resulted in the upregulation of ZO-1 and claudin-4, a sealing claudin (69). However, treatment with CpG-DNA could not restore IL-13 induced barrier dysfunction. This means that inflammation inhibited or at least prevented the beneficial effect of CpG-DNA on restoration of epithelial barrier function in vitro. Nevertheless, a clinical study using TLR-9 agonist, BbG10, showed promising results for the control of asthma symptoms despite steroid withdrawal (70). Treatment with Apolipoprotein A1 also enhanced barrier function. Apolipoprotein A1 is a high-density lipoprotein with anti-inflammatory properties as it suppresses pro-inflammatory ERK signaling and NF-κB activation (71, 72). Apolipoprotein A1 is a key regulator of inflammation in murine models of asthma (73) by promoting recovery of epithelial TJs. In patients with mild-to-moderate persistent asthma, lower levels of lung apolipoprotein A1 were found compared to controls (74). When primary bronchial epithelial cells from mild-to-moderate asthmatics were treated in vitro locally with apolipoprotein A1, occludin and ZO-1 was restored almost to the same levels as found in controls (74). These data suggest that apolipoprotein A1 is a promising therapeutic strategy to repair defective epithelium by promoting the expression of TJs (74).

Lipoxins are biologically active eicosanoids, secreted at sites of inflammation where they have anti-inflammatory properties (75). In vitro stimulation of 16HBE bronchial epithelial cells with lipoxin A4 resulted in a time-dependent increase in TEER with an increase in ZO-1, occludin and claudin-1 expression (76). This barrier promoting effect is mediated via the activation of the protein kinase C signaling pathway, which stimulated the translocation of ZO-1 from the cytosol to the membrane (Figure 2A) (77). Effect of growth factors and cytokines on barrier regulation Growth factors such as epidermal growth factor (EGF) and keratinocyte growth factor have a potential positive effect on epithelial barrier integrity (78). EGF plays a role in maintaining epithelial barrier homeostasis and is involved in healing of damaged airway mucosa (79). EGF prevented oxidative stress-induced barrier disruption and H₂O₂ induced permeability (80, 81) in Caco-2 intestinal epithelial cells. EGF prevented H₂O₂ dependent phosphorylation of occludin and promoted cell growth and cell differentiation. Unlike to intestinal epithelial cells, EGF treatment could not reverse cigarette smoke induced epithelial injury in vitro in primary bronchial epithelial cells (41). In contrast, Transforming Growth Factor-β, produced by almost all cell types in the lung, could prevent cigarette smoke induced barrier disruption by restoring ZO-1 and ZO-2 levels (82). Besides promoting cell growth, EGF also affects the epithelial barrier homeostasis. Treatment of in vitro cultured bronchial epithelial cells from asthmatic patients with EGF resulted in increased baseline barrier function, illustrated by increased TEER and TJ expression of occludin and ZO-1 (41). Interestingly, only apical and not basolateral administration of EGF resulted in upregulation of TJ proteins in bronchial epithelial cells. The apical route of administration may therefore be a possible approach to restore barrier function but formulation, dose and method of administration need to be investigated further to limit the possible side-effects linked with EGF (41). The type 2 cytokines IL-4 and IL-13 are capable of increasing epithelial permeability in 16HBE bronchial epithelial cells (83). The role of these and other cytokines for barrier (dys)function has been reviewed by Georas et al. (77) Epithelial-derived thymic stromal lymphopoietin (TSLP) is considered to be important in the pathogenesis of allergic asthma and allergic rhinitis (84, 85). TSLP is expressed primarily by epithelial cells in response to danger signals. Increased expression of TSLP has been documented in the nasal epithelium of allergic rhinitis patients (86). Although elevated levels of TSLP are linked with allergic diseases, treatment of human nasal epithelial cells with TSLP in vitro rapidly enhanced barrier function with upregulation of occludin, claudin-1, -4 and -7 (86). This suggests that TSLP preserves mucosal barrier function in the early stage of allergic rhinitis by promoting the closure of the nasal epithelial barrier, and as a result the penetration of

Lipoxins are biologically active eicosanoids, secreted at sites of inflammation where they have anti-inflammatory properties (75). In vitro stimulation of 16HBE bronchial epithelial cells with lipoxin A4 resulted in a time-dependent increase in TEER with an increase in ZO-1, occludin and claudin-1 expression (76). This barrier promoting effect is mediated via the activation of the protein kinase C signaling pathway, which stimulated the translocation of ZO-1 from the cytosol to the membrane (Figure 2A) (77). Effect of growth factors and cytokines on barrier regulation Growth factors such as epidermal growth factor (EGF) and keratinocyte growth factor have a potential positive effect on epithelial barrier integrity (78). EGF plays a role in maintaining epithelial barrier homeostasis and is involved in healing of damaged airway mucosa (79). EGF prevented oxidative stress-induced barrier disruption and H₂O₂ induced permeability (80, 81) in Caco-2 intestinal epithelial cells. EGF prevented H₂O₂ dependent phosphorylation of occludin and promoted cell growth and cell differentiation. Unlike to intestinal epithelial cells, EGF treatment could not reverse cigarette smoke induced epithelial injury in vitro in primary bronchial epithelial cells (41). In contrast, Transforming Growth Factor-β, produced by almost all cell types in the lung, could prevent cigarette smoke induced barrier disruption by restoring ZO-1 and ZO-2 levels (82). Besides promoting cell growth, EGF also affects the epithelial barrier homeostasis. Treatment of in vitro cultured bronchial epithelial cells from asthmatic patients with EGF resulted in increased baseline barrier function, illustrated by increased TEER and TJ expression of occludin and ZO-1 (41). Interestingly, only apical and not basolateral administration of EGF resulted in upregulation of TJ proteins in bronchial epithelial cells. The apical route of administration may therefore be a possible approach to restore barrier function but formulation, dose and method of administration need to be investigated further to limit the possible side-effects linked with EGF (41). The type 2 cytokines IL-4 and IL-13 are capable of increasing epithelial permeability in 16HBE bronchial epithelial cells (83). The role of these and other cytokines for barrier (dys)function has been reviewed by Georas et al. (77) Epithelial-derived thymic stromal lymphopoietin (TSLP) is considered to be important in the pathogenesis of allergic asthma and allergic rhinitis (84, 85). TSLP is expressed primarily by epithelial cells in response to danger signals. Increased expression of TSLP has been documented in the nasal epithelium of allergic rhinitis patients (86). Although elevated levels of TSLP are linked with allergic diseases, treatment of human nasal epithelial cells with TSLP in vitro rapidly enhanced barrier function with upregulation of occludin, claudin-1, -4 and -7 (86). This suggests that TSLP preserves mucosal barrier function in the early stage of allergic rhinitis by promoting the closure of the nasal epithelial barrier, and as a result the penetration of
Allergens into the submucosal regions is limited. Regardless of the correlation between TSLP and allergic rhinitis, high TNF levels are found in allergic airway diseases. TNF has been shown to promote epithelial barrier dysfunction by decreasing the expression of occludin, claudins, E-cadherin and p120 catenin. TNF promotes release of TSLP IL-6, IL-8, IL-1β and endogenous TNF. As TNF activates c-src kinases, tyrosine residues on occludin get phosphorylated, which results in the internalization of occludin with opening of the epithelial barrier. SU6656, a c-src kinases antagonist reduced the effect of TNF on epithelial barrier permeability by inhibiting the loss of occludin, E-cadherin and p120 catenin. This illustrates that inhibiting kinases can restore barrier function in bronchial epithelial cells of healthy donors in vitro. Interestingly, when bronchial epithelial cells from severe asthmatics, which have a significant lower TEER compared to those from healthy donors, were exposed in culture to SU6656, there was a significant decrease in macromolecular permeability with an upregulation of occludin, E-cadherin and p120 catenin. SU6656 treatment enhanced the barrier function in patients with asthma, suggesting that topical airway targeting of kinases might become a therapeutic approach to restore barrier function.

Corticosteroids
The first-line treatment of allergic diseases in both upper and lower airways is local application of corticosteroids. The therapeutic effect is mainly attributed to their anti-inflammatory properties resulting in a reduction of the infiltration of inflammatory cells into the affected tissue. In patients with Crohn’s disease, prednisolone treatment resulted in decreased gut permeability in the majority of patients, as reflected by the lactulose/mannitol ratio. This effect is commonly interpreted as a result of the resolution of inflammation. Various studies have however provided evidence that glucocorticoids can promote TJ sealing in the absence of inflammation. Treatment of Caco-2 intestinal epithelial cells with dexamethasone stimulated intestinal barrier function in a time- and dose-dependent manner with an upregulation of claudin-4 and a downregulation of claudin-2. This effect was receptor-dependent and mediated by an increase in MAPK phosphatase-1 expression and activity. Nevertheless, the barrier restoring effect of dexamethasone on TJ expression in Caco-2 intestinal epithelial cells was not confirmed by Bovin et al. They did not find an upregulation of barrier function by dexamethasone or prednisolone. More interestingly, dexamethasone and prednisolone had a protective effect when Caco-2 cells were pre-exposed to TNF. This effect could be explained by corticosteroid induced suppression of the TNF induced increase in myosin light chain kinase gene activity, protein expression, and subsequent opening of the intestinal TJ barrier.

Compared to the intestine, little is known about the effect of corticosteroids in both upper and lower airways. Treatment of 2 bronchial epithelial cell lines, i.e. Calu-3 and 16HBE, with dexamethasone and fluticasone propionate resulted in an increased epithelial barrier integrity by stimulating the expression of occludin and ZO-1. Our group recently showed that fluticasone propionate enhanced barrier integrity in primary nasal epithelial cells from both healthy controls and house dust mite allergic rhinitis patients. Moreover, allergic rhinitis patients using steroids on a daily basis had a significantly stronger barrier function compared to patients not using steroids.

The positive effect of corticosteroids on TJs is orchestrated via different molecular mechanisms (Figure 2C). Corticosteroids stimulate the MAPK phosphatase-1 pathway, which regulates the anti-inflammatory effects of corticosteroids by dephosphorylating ERK and p38. Besides MAPK phosphatase-1, myosin light chain kinases also play a central role in the regulation of epithelial TJ permeability. Activated myosin light chain kinases phosphorylate myosin light chain and stimulate the contraction of the peri-junctional actomyosin ring. As a result, TJs are internalized and therefore the TJ opens. Corticosteroid treatment inhibits myosin light chain kinase and thus inhibits the internalization of TJs.

In summary, different treatment strategies can result in the restoration of impaired epithelial barrier function, providing new insights and new therapeutic targets for allergic airway diseases.

Unmet needs to nasal barrier dysfunction
Allergic rhinitis, which is defined as a symptomatic inflammation of the nasal mucosa, affects up to 30% of the total population. Despite the different treatment modalities like inhaled steroids, anti-histamines, leukotriene receptor antagonists and immunotherapy, there is still a fraction of patients that is uncontrolled with adequate therapy. Identifying these difficult-to-treat patients is of crucial importance, as nasal epithelial barrier defects may play a pivotal role in uncontrolled disease. Nonetheless, compared to the gastrointestinal tract, no clinical test is available to evaluate nasal epithelial barrier function in vitro. In the gastrointestinal tract, the lactulose/mannitol ratio can be used to measure small intestinal permeability, providing information about the degree of epithelial damage. It would therefore be of great interest to be able to investigate in a clinical setting barrier dysfunction in patients with allergic rhinitis. This will help us better understand the pathology of allergic rhinitis. Moreover, using a clinical diagnostic test, the success of different treatment options can be evaluated which will help us understand why more than 20% of patients are uncontrolled.

Conclusion
Epithelial barrier defects are linked with pathology in the airways, gut and skin. Whether barrier defects represent a primary
genetic defect or a secondary phenomenon resulting from inflammatory mechanisms needs to be investigated further. Restoring barrier function or preventing barrier damage may represent a new treatment target. The development of molecules that restore or at least up-regulate epithelial barrier integrity might be very useful for treatment of allergic diseases, especially in difficult-to-treat patients who fail to respond to conventional therapy.

Authorship contribution
BS performed literature review and drafted the manuscript. SFS and JLC performed a critical review of the manuscript and significantly contributed to the manuscript draft and editing. GB, CAA and PHW performed a critical review of the manuscript.

Disclosures
The authors are supported by grants from the Belgian Federal Government (IUAP P7/30), the institute for Science and technology Flanders (IWT) (TBM project 130260) and the research council of the KU Leuven (GOA 2009/07 and 14/011). P.W.H. is a recipient of a senior researcher fellowship from the Fund of Scientific Research (FWO), Flanders, Belgium. S.F.S. supported by the research council of KU Leuven (PD/MK/14/189).

References
38. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of func-
40. de Boer WI, Sharma HS, Baelemanis SM, Hoogsteden HC, Lambrecht BN, Braunstahl GJ. Altered expression of epithelial junctional-
56 e12-12.
sinusitis: the regulation of tight junc-
47. Nicodemos-Johnson J, Naughton KA, Sudi RJ, Widdicombe JH. Calu-3: a human air-
way epithelial cell line that shows cAMP-
95.
50. Hox V, Vanairobeek JA, Callebaut I, Bobic S, Do Vught V, Ceuppens J, et al. Airway exposure to hypochlorite prior to ovalbu-
54. Ramapathy S, Esmaeili F, Paschoud S, Sublet E, Citi S, Borchard G. Toll-like receptor 2 regulates the barrier function of human bron-
chial epithelial monolayers through atypical protein kinase C zeta, and an increase in expression of claudin-1. Tissue Barriers 2014; 2:e29166.
58. Merkle HP, Ditzinger G, Lang SR, Peter H, Schmidt MC. In vitro cell models to study nasal mucosal permeability and metabo-
60. Shen BQ, Finkbeiner WE, Wine JJ, Mrnsy RJ, Widdicombe JH. Calu-3: a human air-
way epithelial cell line that shows cAMP-
95.
63. Hox V, Vanairobeek JA, Callebaut I, Bobic S, Do Vught V, Ceuppens J, et al. Airway exposure to hypochlorite prior to ovalbu-
65. Ramapathy S, Esmaeili F, Paschoud S, Sublet E, Citi S, Borchard G. Toll-like receptor 2 regulates the barrier function of human bron-
chial epithelial monolayers through atypical protein kinase C zeta, and an increase in expression of claudin-1. Tissue Barriers 2014; 2:e29166.
tion and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A. J Biol Chem 2002; 277:4247-54.